Leadership Team
Meet our experienced team.
Accelerate your timeline to the clinic or the market with our expertise in complex chemistry and bioconjugation services.
Bioconjugates & Antibody-Drug Conjugates (ADCs) offer a complex development and manufacturing challenge. Abzena’s experience in bioconjugation services and complete end to end solution simplifies the development process, and accelerates timelines to reach the clinic or market. Our specialized services for bioconjugates & ADCs provide:
We design and deliver tailored solutions for small molecule intermediates including high potency chemistry, linker payloads, payload-linker chemical intermediates, bioconjugation and antibody-drug conjugates (ADCs). We support partners with the design, synthesis and manufacture of payloads and payload-linker constructs for ADC and bioconjugation.
Leveraging our experience in the synthesis of payloads, linkers, and payload-linker chemical intermediate constructs we enable rapid generation of structure activity relationships (SAR) of various linker combinations with your new payloads. We identify the most suitable linker for your ADC profile.
Moving medicines created with ADCs, bioconjugates and linker payloads forward is where we are at our best. This has made Abzena the leading, fully integrated, bioconjugate contract development and manufacturing services provider through to commercialization.
Our capabilities include:
Our knowledge of cGMP manufacturing enables us to successfully transfer existing processes into our facilities or develop a new innovative process, when needed, to meet your program needs.
Our processes follow ICH Product Lifecycle guidelines which ensure a robust and well characterized scalable manufacturing process.
Utilizing analytics, we ensure the right product quality attributes for your program.
We continue to pursue advances in technology, processes and knowledge to keep ourselves and our customers at the forefront of innovation. Our agility and dedication mean we can streamline your program and mitigate project risk while producing groundbreaking treatments.
Our unique ThioBridge™ conjugation technology has been proven to enhance ADC development by overcoming issues with existing technologies in order to improve stability, potency, and efficacy. If you are looking to rapidly move your ADC program to its next regulatory or clinical milestone, access our latest information on ThioBridge™ today to learn how.
The asset you’re developing right now can make a real difference for human health. Let us use our wealth of experience to deploy the best technologies, shorten lead times and implement effective risk mitigation strategies.
The leading biologics CDMO + CRO that accelerates drug development, moving medicine forward for patients in need.